Loading patent…
AssigneeEmbold Therapeutics, Inc.
InventorsJacob Hansen Artz, Rachel Cathleen Botham, Xingxiu Chen, Victorino Miguel Francisco, William Casey Hallows, Jeremiah Dallas Heredia, Londen Christine Johnson, Douglas Chamberlain Millar, Ouma Onguka, Christopher Edward Schmitt, Adam P. Silverman
Estimating the term…
The present disclosure provides engineered glucocerebrosidases, polynucleotides encoding the engineered glucocerebrosidases, and methods of treating a deficiency in glucocerebroside activity using the engineered glucocerebrosidases or the recombinant polynucleotides encoding the engineered glucocerebrosidases.
An engineered glucocerebrosidase, or a biologically active fragment thereof, comprising an amino acid sequence having at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to a reference sequence corresponding to residues 40-536 of SEQ ID NO:
Dependencies are inferred from the claim text.